Report : South America Cervical Cancer Diagnostic Testing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (PAP Testing, HPV Testing, Colposcopy, Cervical Biopsies, Cystoscopy, and Others) and Service Provider (Diagnostics and Research Laboratories, Hospitals and Clinics, Specialty Clinics, and Home Care Services)Â Â Â Â
HPV Testing Segment is Expected to be Fastest Growing During Forecast Period for SAM Region
According to a new market research study on “SAM Cervical Cancer Diagnostic Testing Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Type and Service Provider” is expected to reach US$ 491.80 million by 2028 from US$ 366.73 million in 2021. The market is estimated to grow at a CAGR of 4.3% from 2021 to 2028. The report provides trends prevailing in the SAM cervical cancer diagnostic testing market along with the drivers and restraints pertaining to the market growth. Development and launch of innovative products and development opportunities in emerging countries are the major factor driving the growth of the SAM cervical cancer diagnostic testing market. However, lack of awareness about diagnosis and treatment methods hinders the growth of SAM cervical cancer diagnostic testing market.
In case of COVID-19, SAM is highly affected especially Brazil. The COVID-19 pandemic has placed unequalled demands on the health system. This led to delays in the initiation and completion of cancer treatment. The long-term health consequences can be assessed because of the delay in diagnosis and treatment for cervical cancer due to COVID-19. The COVID? 19 pandemic is a critical test for the already overburdened and underfunded public healthcare systems of SAM. It suffers from severe inequalities. With a vast population living in poverty, SAM continuously face widespread health problems due to overcrowding, limited sanitation, food insecurity, and unpredictable environmental conditions. Underfunded state?run hospitals are the only source of medical care in the region. Brazil is in a critical situation due to COVID-19. Lack of resources is creating more challenges in the region, hampering the growth of the brain cancer diagnostics market. All these factors will restrict the distribution and adoption of diagnostics products and services which will restrict the market growth. Delays in diagnosis and treatment are likely to lead to more cervical cancer deaths as compared to COVID-19 mortality preclude among the patients with cervical cancer. Health systems must rearrange in terms of priority setting for provision of care, starting with prioritizing the treatment of patients with early-stage cervical cancer, increasing adoption of tele consultation, and reinforcing the role of primary care physicians in provision of cancer care. Hence, impact of pandemic will become moderated on the cervical cancer diagnostic testing market.
The SAM cervical cancer diagnostic testing market has been segmented based on type, service provider, and country. Based on type, the market has been segmented into PAP testing, HPV testing, colposcopy, cervical biopsies, cystoscopy, and others. The PAP testing segment dominated the market in 2020 and HPV testing segment is expected to be fastest growing during forecast period. Based on service provider, the market has been segmented into diagnostics and research laboratories, hospitals and clinics, specialty clinics, and home care services. The diagnostics and research laboratories segment dominated the market in 2020 and same segment is expected to be fastest growing during forecast period. Based on country, the market has been segmented into Brazil, Argentina, and rest of SAM.
Abbott; BD; Cooper Companies, Inc.; F. Hoffmann-La Roche Ltd.; Femasys Inc.; Guided Therapeutics, Inc; Hologic, Inc.; QIAGEN; and Quest Diagnostics Incorporated are among the leading companies in the SAM cervical cancer diagnostic testing market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2020, F.hoffamnn-La-Roche LTD. announced FDA approval for the expanded use of CINtec PLUS Cytology, the first triage test based on biomarker technology for women whose cervical cancer screening results are positive for high-risk types of human papillomavirus (HPV).
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com